PharmTech Drug Digest 11.20
News|Articles|November 2, 2015

PTSM: Pharmaceutical Technology Sourcing and Management

  • PTSM: Pharmaceutical Technology Sourcing and Management-11-04-2015
  • Volume 11
  • Issue 11

Xcelience Opens New Headquarters

CDMO Xcelience opens new facility in Tampa, FL, for formulation and analytical services.

Xcelience, a contract development and manufacturer (CDMO), has announced the opening of a new 71,000-sq-ft headquarters at 4910 Savarese Circle in Tampa, FL.  The building houses preformulation and formulation development labs and suites, executive headquarters, and analytical and stability services.  An official ribbon cutting ceremony on Oct. 30, 2015 was attended by Florida Governor Rick Scott, Tampa Mayor Bob Buckhorn, and other elected and non-elected officials. 

The company’s previous headquarters on West Laurel Street in Tampa will transition to provide clinical trial and small-scale commercial manufacturing. 

In July 2015, Xcelience made a structured cash investment in Powdersize, a Pennsylvania-based company specializing in milling, micronization, and powder size, adding particle size control solutions to Xcelience’s portfolio of capabilities.

Xcelience provides services from preformulation through global clinical supplies packaging and distribution to international pharmaceutical and biotechnology clients for Phases I-IV.  Since its inception in 2006, the company has grown from one facility with 45 employees to an international CDMO provider, with seven facilities and more than 200 employees.

Source: Xcelience

 

 

 


Related to this article

Are Your Supplier Selection and Oversight Processes Robust Enough?
Despite best efforts to ensure a contract organization is following GMPs, a warning letter is issued by the FDA. Susan J. Schniepp, distinguished fellow at Nelson Labs, and Siegfried Schmitt, PhD, vice president, Technical at Parexel, provide advice for create a robust supplier selection and oversight system.
Transitioning mRNA from R&D to GMP
Marco Pupo, PhD, innovation and development coordinator at Anemocyte, discusses the R&D-to-GMP transition and the changing shape of mRNA manufacturing facilities.
white pill capsule isolated on white background | Image Credit: ©F16-ISO100 -stock.adobe.com
PharmTech spoke with Chiara Bergerone, deputy CEO of Roquette’s Health & Pharma Solutions Business, about the company’s hydroxypropyl methylcellulose (HPMC) capsule, which was previewed at CPHI Milan 2026 in October.